Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 46% Improvement Relative Risk Coll et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 635 patients in Spain Lower mortality with HCQ (p=0.000018) Coll et al., American J. Transplantation, doi:10.1111/ajt.16369 Favors HCQ Favors control
Covid-19 in transplant recipients: the spanish experience
Coll et al., American Journal of Transplantation, doi:10.1111/ajt.16369
Coll et al., Covid-19 in transplant recipients: the spanish experience, American Journal of Transplantation, doi:10.1111/ajt.16369
Oct 2020   Source   PDF  
  All Studies   Meta
Retrospective 652 transplant recipient patients in Spain showing 46% lower mortality for patients treated with HCQ, unadjusted relative risk RR 0.54, p<0.0001. This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
risk of death, 45.6% lower, RR 0.54, p < 0.001, treatment 55 of 307 (17.9%), control 108 of 328 (32.9%), NNT 6.7.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Coll et al., 23 Oct 2020, retrospective, Spain, peer-reviewed, median age 61.0, 29 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Accepted Article DR MARIO FERNÁNDEZ-RUIZ (Orcid ID : 0000-0002-0315-8001) DR MARTA CRESPO (Orcid ID : 0000-0001-6992-6379) DR FRANCESC MORESO (Orcid ID : 0000-0002-7267-3963) MISS MARÍA OVIDIA LÓPEZ-OLIVA (Orcid ID : 0000-0003-3503-3518) MR. EDOARDO MELILLI (Orcid ID : 0000-0001-6965-3745) DR LAURA LLADO (Orcid ID : 0000-0002-3717-3306) DR CARMELO LOINAZ SEGUROLA (Orcid ID : 0000-0002-1873-0568) DR DOMINGO HERNANDEZ (Orcid ID : 0000-0001-5469-2119) DR BEATRIZ DOMÍNGUEZ-GIL (Orcid ID : 0000-0002-5695-8993) Article type : O - Original Article COVID-19 IN TRANSPLANT RECIPIENTS: THE SPANISH EXPERIENCE Elisabeth Coll1; Mario Fernández-Ruiz2; J. Emilio Sánchez-Álvarez3; José Ramón Martínez-Fernández1; Marta Crespo4; Jorge Gayoso1; Teresa Bada-Bosch5; Federico Oppenheimer6; Francesc Moreso7; María O. López-Oliva8; Edoardo Melilli9; Mª Luisa Rodríguez-Ferrero10; Elena Burgos11; Carme Facundo12; Inmaculada Lorenzo13; Íñigo Yañez14; Cristina Galeano15; Ana Roca16; Mercedes Cabello17; Manuel GómezBueno18; Javier Graus19; Laura Lladó20; Alicia de Pablo21; Carmelo Loinaz22; Beatriz Aguado23; Domingo Hernández24; Beatriz Domínguez-Gil1, on behalf of the Spanish Group for the Study of COVID-19 in Transplant Recipients. 1. Organización Nacional de Trasplantes (Spanish National Transplant Organization). This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/AJT.16369 This article is protected by copyright. All rights reserved Accepted Article 2. Unit of Infectious Diseases, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain. Group for the Study of Infection in Transplantation and the Immunocompromised Host (GESITRA-IC) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). 3. Department of Nephrology. Hospital Universitario de Cabueñes, Gijón, Spain. Spanish Society of Nephrology (SEN). 4. Department of Nephrology. Hospital del Mar, Barcelona, Spain. Transplant Working Group of the Spanish Society of Nephrology (SEN). REDinREN (RD16/0009/0013). 5. Department of Nephrology. Hospital Universitario 12 de Octubre, Madrid, Spain. 6. Department of Nephrology. Hospital Clinic, Barcelona, Spain. 7. Kidney Transplant Unit. Department of Nephrology. Hospital Universitario Vall d´Hebrón, Barcelona, Spain. 8. Department oof Nephrology. Hospital Universitario La Paz, Madrid, Spain. 9. Kidney Transplant Unit, Department of Nephrology. Hospital Universitario de Bellvitge, Barcelona, Spain. 10. Department of Nephrology. Hospital General Universitario Gregorio Marañón, Madrid, Spain. 11. Department of Nephrology. Hospital Germans Trias i Pujol, Badalona, Spain. 12. Kidney Transplant Unit. Fundación Puigvert, Barcelona, Spain. 13. Department of Nephrology. Complejo Hospitalario Universitario de Albacete, Albacete, Spain. 14. Department of Nephrology. Hospital Universitario de Cruces, Barakaldo, Spain. 15. Kidney Transplant Unit. Hospital Universitario Ramón y Cajal, Madrid, Spain. 16. Department of Nephrology. Complejo Hospitalario Universitario de Toledo, Toledo, Spain. 17. Department of Nephrology. Hospital Regional Universitario de Málaga, Málaga, Spain. 18. Department of Cardiology. Hospital Universitario Puerta de Hierro,..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop